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Abstract
Background: With the use of medicines being a broad and extensive part of health management, mechanisms to
ensure quality use of medicines are essential. Drug usage evaluation (DUE) is an evidence-based quality
improvement methodology, designed to improve the quality, safety and cost-effectiveness of drug use. The
purpose of this paper is to describe a national DUE methodology used to improve health care delivery across the
continuum through multi-faceted intervention involving audit and feedback, academic detailing and system
change, and a qualitative assessment of the methodology, as illustrated by the Acute Postoperative Pain
Management (APOP) project.
Methods: An established methodology, consisting of a baseline audit of inpatient medical records, structured
patient interviews and general practitioner surveys, followed by an educational intervention and follow-up audit, is
used. Australian hospitals, including private, public, metropolitan and regional, are invited to participate on a
voluntary basis. De-identified data collected by hospitals are collated and evaluated nationally to provide
descriptive comparative analyses. Hospitals benchmark their practices against state and national results to facilitate
change. The educational intervention consists of academic detailing, group education, audit and feedback, point-
of-prescribing prompts and system changes. A repeat data collection is undertaken to assess changes in practice.
An online qualitative survey was undertaken to evaluate the APOP program. Qualitative assessment of hospitals’
perceptions of the effectiveness of the overall DUE methodology and changes in procedure/prescribing/policy/
clinical practice which resulted from participation were elicited.
Results: 62 hospitals participated in the APOP project. Among 23 respondents to the evaluation survey, 18 (78%) reported
improvements in the documentation of pain scores at their hospital. 15 (65%) strongly agreed or agreed that participation
in APOP directly resulted in increased prescribing of multimodal analgesia for pain relief in postoperative patients.
Conclusions: This national DUE program has facilitated the engagement and participation of a number of acute
health care facilities to address issues relating to quality use of medicine. This approach has been perceived to be
effective in helping them achieve improvements in patient care.
Background
The use of medicines is the most common health-related
action taken by Australians, particularly those with
chronic diseases [1]. With such a broad and extensive use
of medicines as part of health management, mechanisms
to ensure quality use of medicines are essential [2]. Drug
usage evaluation (DUE) is an evidence-based quality
improvement methodology, designed to improve the
quality, safety and cost-effectiveness of drug use [3,4].
DUE or drug utilisation review (DUR) involves an initial
four step process of: 1. identification of a quality use of
medicine problem e.g. low concordance with an accepted
prescribing guideline, 2. collection of baseline data to
quantify the problem, 3. feedback of results (evaluated
data) to prescribers and other stakeholders, and 4. imple-
mentation of an intervention to improve practice. Ideally,
this process of audit and feedback is repeated to continue
to assess practice and identify gaps as in Figure 1.
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Australia formed state-based special interest groups that
carried out multisite audits of drug use [5-7]. Participation
in multisite DUE projects enabled hospitals to compare
their practice with others and enabled smaller hospitals
with limited resources/capacity to carry out DUE. Some of
the state-based audits were sponsored by the NPS - Better
choices, Better Health (NPS), an independent, non-profit
organization, funded by the Australian Government
Department of Health and Ageing. The NPS provides evi-
dence-based information about medicines, and educational
and behaviour change strategies for health professionals
and consumers. In 2001 the NPS funded five state Thera-
peutic Advisory/DUE Groups to conduct separate multi-
site initiatives [8-12]. Topics for each state were based on
local needs analysis, and the projects comprised audit and
feedback and subsequent re-audit. Based on an assessment
of the achievements, barriers and enablers of state-based
projects, the NPS in 2003 funded and coordinated the
state Therapeutic Advisory/DUE groups to work colla-
boratively to address quality use of medicine issues at a
national level for hospitals.
Published DUEs mostly present an initial clinical audit
only and tended to be localised in nature [13]. A recent
systematic review of the literature demonstrated a
greater chance of success in changing behaviour with
regards to medication use when a number of different
interventions are used [14]. The national DUE program
aimed to implement the complete DUE cycle, including
a baseline audit, multifaceted interventions and post-
intervention audits. We describe a model of national
multisite DUE and its evaluation, as illustrated by the
Acute Postoperative Pain (APOP) project.
Methods
This model utilises an established quality improvement
methodology, DUE, as described previously. This involves
hospitals collecting baseline audit data, feedback of evalu-
ated data, targeted educational interventions, a repeat
audit and feedback on improvements in practice. At least
one complete DUE cycle is implemented during the
course of each 2-year project.
Topic selection
The state Therapeutic Advisory/DUE groups consult
with their hospital members and affiliated academic units
to identify a therapeutic area that may benefit from a
quality improvement initiative. Key criteria for topic
selection are outlined below.
The topic selected should have:
￿ A disease state or therapy-based focus
￿ Evidence-based national guidelines of best practice
available
￿ A quantitative/qualitative gap in evidence-based
practice
￿ Potential for engagement with hospital physicians in
a shared quality agenda
￿ Alignment with national health priorities
￿ Potential for synergy withp r o g r a m su n d e r t a k e nb y
other agencies
￿ Potential to improve patient care across the conti-
nuum of care
￿ Potential to link with primary healthcare providers
￿ A significant positive impact on patient care
￿ Support for sustainable quality improvement activity
(capacity and skills in hospitals) and embed quality use
of medicine practices into hospital systems
Project governance
The project is managed by the national project team com-
prising NPS staff members (project lead, data analyst and
database/website developers) and the project officer and
lead from each of the state-based Therapeutic Advisory/
DUE groups. State project committees are established and
comprise at least one member from participating hospitals
and selected key medical, nursing and pharmacy clinicians
from the state with expertise in disease/therapeutic area.
A national expert reference group is established to
guide the national project team and consists of members
nominated by key specialist organizations. The expert
reference group provides advice on gaps in evidence-
based practice, project objectives, quality measures for
improvement, and reviews the key messages and educa-
tional materials. For the APOP project this group con-
sisted of members from the Australian and New Zealand
College of Anaesthetists and the Faculty of Pain Medi-
cine. The organisational structure is seen in Figure 2.
Hospital recruitment
Australian hospitals, private and public, metropolitan
and regional, are invited to participate via the state
Figure 1 The Drug Use Evaluation Cycle.R e p r o d u c e df r o mt h e
Standards of Practice for Drug Use Evaluation in Australian Hospitals,
courtesy of the Society of Hospital Pharmacists of Australia [3].
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ethics application is made as required by individual hos-
pital ethics committees using the National Ethics Appli-
cation Form [15] where accepted. Hospitals are provided
with some financial support from NPS to assist with
implementation of the project. Participating hospitals
appoint a local hospital coordinator, whose responsibil-
ities are to: liaise with the state project officer, recruit a
local hospital project team, coordinate and facilitate pro-
ject activities including data collection, feedback of
results within the hospital, and organise educational
activities and system changes where necessary. A local
opinion leader, who is seen as an expert within the ther-
apeutic area, is sought to support and endorse local pro-
ject activity. A project team consisting of the local
hospital coordinator, local opinion leader, medical, nur-
sing and pharmacy clinicians working in the therapeutic
area and, where available, a clinical governance/quality
manager is formed.
Data collection
Patient inclusion criteria and the dataset are determined
by the national project team. The dataset includes patient
demographics, relevant clinical data and prescribed medi-
cines, information on the patients’ experience of care, and
information from the General Practitioner (GP) on the
quality of the discharge communication. Each hospital is
responsible for collecting its own data, via the inpatient
medical record review, structured patient interview and
GP survey.
 
National coordinating and funding body:  
NPS- Better choices, Better health (project lead, 
data analyst, database/website developers) 
State Therapeutic Advisory Groups 
State Drug Use Evaluation Groups 
Local Project Committee in individual hospital 
Hospital opinion leader 
Hospital coordinator 
Clinical governance/quality manager where available 
Medical, nursing and pharmacy clinicians working in the therapeutic area 




Experts in topic from medical, nursing and pharmacy disciplines 
National project team 
National Expert Reference Group 
including representatives from Faculty 
of Pain Medicine, Australia New 
Zealand College of Anaesthetists 
Figure 2 Flow chart of the organisational structure for the national Drug Use Evaluation program for hospitals.
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mentation of preoperative patient education and post-
operative pain assessment, postoperative analgesic
prescribing and administration, monitoring and docu-
mentation of adverse effects, documentation of pain
management plans at discharge, the patient’se x p e r i e n c e
of pain management in hospital and following discharge,
and the adequacy of communication to the GP about on-
going pain management.
Data are collected and then de-identified data are
entered into a specifically designed web-based database
(electronic-DUE audit tool). The electronic-DUE audit
tool is a secure, password protected electronic database
developed by the NPS [16]. The tool generates auto-
mated feedback reports for each hospital (in real time),
reporting key quality measures. Hospital de-identified
data are submitted electronically via the electronic-DUE
audit tool in an encrypted file to the NPS for central
collation and analysis. This comparative analysis enables
each hospital to compare their baseline practice and
subsequent improvements to state and national data. In
APOP the quality measures included documentation of
pain assessment, postoperative analgesic prescribing,
patient satisfaction with pain management and commu-
nication of the discharge pain management plan to the
patient/carer and GP.
Intervention
A multifaceted intervention strategy is used to deliver
nationally-developed best practice guidance in the form
of key messages for the project. Academic detailing (edu-
cational outreach, educational visiting) by trained detai-
lers is the key intervention [17]. Each hospital nominates
up to two staff members (medical, nursing or pharmacy)
from relevant specialty areas to be trained in academic
detailing skills. Two-day workshops for approximately
twenty participants each, conducted by the Drug and
Therapeutic Information Service (Adelaide) and NPS, are
held. Participants are trained in the theory and practice
of academic detailing and the evidence behind the key
messages, using didactic sessions, small group work and
role plays with other health professionals. The target
audience for the academic detailing is determined by the
hospital and includes key opinion leaders, senior and
junior medical officers, nursing staff, pharmacists and
other allied health members.
For the APOP project, education was addressed to
medical, nursing, pharmacy and allied health staff work-
ing in surgical and anaesthetic areas. For nursing staff
the focus was the use of pain and sedation scores, and
for medical staff education focused on the importance
of communication to the patient and GP at discharge.
The evidence for prescription of multimodal analgesia,
multiple anti-emetic options and prophylactic laxatives
for patients prescribed opioids was emphasised to all
groups.
Other interventions include point-of-prescribing
prompts (e.g. reminder bookmark), promotional material
(e.g. wall posters) and a feedback presentation with com-
parative state and national data, provided for local adap-
tation by each hospital. System changes are implemented
at the discretion of the hospital project team.
Evaluation
A short qualitative survey designed in consultation with
state-based Therapeutic Advisory/DUE groups was under-
taken by NPS between December 2009 and February
2010. The main aims of the survey were to establish: hos-
pitals’ perceptions of the effectiveness of the overall DUE
methodology and the changes in procedure/prescribing/
policy/clinical practice which resulted from participation
in one of the three national DUE projects [18-20]. Ques-
tions were selected on the basis of eliciting quality assur-
ance/improvement responses and to probe responses
regarding the varying stages of the DUE cycle. The survey
questions can be found in additional file 1. (Note: Results
displayed below are for questions relating to APOP only).
Questions were embedded into the online surveying
and data collection tool - Survey Monkey
(R). A link to the
survey was emailed to a list of participating staff at hospi-
tals, in New South Wales, Victoria, Tasmania, Queens-
land and South Australia. Recipients on that list were
those who had an active involvement in a DUE project.
The list was provided by state coordinators of the DUE
projects. Responses were coded and grouped into themes




62 hospitals (31 principal referral, 10 large major city, 10
private, 5 large regional and remote, 3 medium major
city/regional, 2 specialist women’s/children’s hospitals
and 1 private regional hospital collaborative) from all
states and territories participated in APOP. Results
regarding APOP have been previously published [19].
The evaluation survey was sent to 72 nominated indi-
viduals. 37 recipients had participated in the APOP pro-
ject. 23 (62%) of these 37 respondents to the evaluation
survey reported being involved in the APOP project.
Changes in practice
78% (n = 18) of the 23 APOP respondents agreed or
strongly agreed that documentation of pain scores
increased at their facility as a result of APOP. Responses
elaborating on these changes were grouped into two
themes: awareness of best practice (via in-service educa-
tion) resulting in improved local practice and system
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changes included a bedside pain prompt, changes in
observation forms, additional posters and patient educa-
tion leaflets. Some hospitals reported that the changes
to observation charts had occurred at a state level.
Comments included:
‘I think pain score documentation increased simply
because of an increased awareness among staff of the
use of pain scores as the 5th vital sign. There was a
number of ward in-services given re: APOP and the
use of pain scores. The inclusion of a pain score was
already part of the observation chart.’
‘The Nurses on the Orthopaedic ward were actively
involved and really did take this to town. They
started recording pain at rest and pain at movement
on their Ob’s charts [observation chart] where pre-
v i o u s l yt h e yh a do n l yr e c o r d e d‘pain at rest’.T h e y
had the key message of ‘Please remember to record
your pain score’ on the outside cover of each pts
[patients] bedside file’
Fifteen respondents (65%) strongly agreed or agreed
that participation in APOP directly resulted in increased
prescribing of multimodal analgesia for pain relief in
postoperative patients. Four respondents commented
that the prescription of multimodal analgesia was
already done well, but enhanced with increased involve-
ment by pharmacists:
‘Prescription of multimodal analgesia was already
practiced in this hospital, however staff became more
aware of rationale behind this and reduced co-pre-
scription of same/similar drugs e.g. Panadeine Forte +
Oxycodone’
‘We were already adopting the multimodal approach
but it was great to reinforce this. If for some reason it
was not being used the Pharmacists were educated to
question say why the regular paracetamol was not
prescribed and could quite easily back it up with the
literature’
One hospital reported a mandatory Junior Medical
Officer pain management orientation program devised
by the Acute Pain Service to improve the prescribing of
analgesics. Another hospital reported on the frequent
changeover of staff and the need to repeat education to
sustain improvements in the prescribing of multimodal
analgesia.
Ten of the respondents (43%) involved in the APOP
DUE indicated that it resulted in an increased provision
of postoperative pain management plans at discharge to
patients and GPs. Seven (30%) indicated that there was
no change at their hospital and two respondents dis-
a g r e e do rs t r o n g l yd i s a g r e e dt h a tA P O Pr e s u l t e di n
increased pain management plans at discharge for
patients. One respondent indicated that this was a time
management issue for their medical staff and two
respondents commented that it was either undertaken
by the pharmacist or on prompting by the pharmacist.
Four respondents described the development of infor-
mation brochures for patients at discharge, along with
development of electronic discharge summaries and dis-
charge medication lists provided by pharmacists.
‘Patient information leaflets were developed detailing
drugs given at discharge. These were also faxed to
GP on discharge. GP survey indicated improvement’
‘Basically the Drs [doctors] always had to be
prompted to make headway with this element of the
project. The medication discharge summaries that we
use are practically illegible ie the copy that goes with
t h ep tt ot a k et ot h e i rl o c a lD r .H o w e v e ri ft h a tp t
[patients] was seen by a Pharmacist this aspect would
be done well and a Medilist would be supplied too’
DUE methodology
With regard to feedback on DUE methodology, 18 (78%)
responses were received about the effectiveness of the
DUE projects on improving quality use of medicines.
These were grouped into a number of themes as seen in
Table 1.
One respondent summed up their feeling regarding
the overall DUE methodology:
‘The DUE project provided an infrastructure - data
collection, analysis, intervention, and follow-up - which
allows the hospital to focus on a particular area that
may otherwise not happen. There is little time available
in hospitals to develop all the necessary materials to con-
duct such quality improvement activities in isolation.
Providing deadlines meant the work got done. Providing
training in communication via academic detailing facili-
tated effective inter-professional communication around
key messages. It became more about working together not
about one person telling someone else what to do.’
Facilitators of change
Respondents were provided a list of examples that may
have facilitated change in their hospital (feedback of hospi-
tal data benchmarked against state and national, involve-
ment of Drug and Therapeutic Committees, involvement
of Senior Clinician, endorsement, provision of educational
resources for patients and hospital staff). Nine of the com-
ments received focused particularly on the success that
benchmarking and feedback had in facilitating change.
Pulver et al. BMC Health Services Research 2011, 11:206
http://www.biomedcentral.com/1472-6963/11/206
Page 5 of 8‘Benchmarking showed improvement with implemen-
tation of education programs and development of
patient information. Projects have been actively
endorsed by Pharmacy & Therapeutics Committee.
Provision of education for staff (both medical, nursing
and allied health) has facilitated change in the hos-
pital setting with assisted use of DUE’sp r o g r a m
templates and checklists.’




We describe a unique model of a national multisite DUE
program. Our model protects the privacy of the data from
individual hospitals while allowing for comparisons
between the participating hospital, and aggregated state
and national results. Participation in a nationally coordi-
nated program, with education resources and training pro-
vided, enables hospitals to undertake the DUE, with
efficient use of local resources. Hospitals are provided with
support/assistance at all stages by state project officers.
A multifaceted educational intervention strategy is
employed as part of the overall methodology, allowing
hospitals to select and tailor the intervention tools
according to local need, to influence clinician behavior.
There is an increasing international recognition of aca-
demic detailing as an important evidence-based strategy
for influencing behavior change among health profes-
sionals [17,21-24]. A review by Wensing and Grol found
positive effects, mainly on prescribing behavior when
academic detailing was used as part of a multifaceted
intervention including audit and feedback and reminders
[25]. Academic detailing has been used by NPS in Aus-
tralia to improve quality use of medicine in the general
practice setting. In the national DUE program hospital
staff were trained in skills for professional communica-
tion to influence behaviour change. These skills may be
used in other local initiatives and in everyday practice.
Our model gives participating hospitals immediate
access to their own results as well as enabling
benchmarking with state and national results. Respon-
dents to the evaluation survey reflected that feedback of
current practice and benchmarking was particularly use-
ful. Participation may also enable hospitals to meet
local, state and national standards/indicators/accredita-
tion requirements. Factors that facilitate implementation
of a multisite project are described below.
Factors that facilitate implementation of a multisite
project
￿ A national coordinating body
￿ Experienced state project officers
￿ Provision of a small financial incentive
￿ Use of an evidence-based intervention method (aca-
demic detailing) as part of a multi-faceted intervention
￿ Use of an electronic data collection tool with auto-
mated feedback in real-time
￿ Engagement of enthusiastic hospital staff
The undertaking of a multisite DUE program has some
challenges. Firstly national consensus is required in
selecting a therapeutic area of interest and priority. Con-
sensus amongst clinicians regarding appropriate manage-
ment (best practice) within the selected area is also
required. To facilitate national consensus, identification
of best-practice guidance is required e.g. in Australia we
have the Therapeutic Guidelines [26] and other national
guidelines. With data being collected across many sites,
the use of a manual to guide data collection is essential
to ensure data integrity. In the current model submitted
data are checked for obvious discrepancies; however
potential misinterpretation of data elements by local data
collectors is not assessed during the data collection pro-
cess. This is a limitation of the multisite methodology,
and could be overcome by random audits of data collec-
tion at the various sites by state project officers. The cost
effectiveness of academic detailing has not been evalu-
ated. It is unclear whether the impact of the multifaceted
intervention is sustained over time [27].
In the current national DUE model financial support
offered to hospitals is a contribution only, with the
expectation that hospitals will provide support in kind
towards project completion. Reliance on the funding
Table 1 Feedback from respondents on drug use evaluation methodology
Theme Examples of comments
Better prescribing Improved analgesic prescribing by JMOs [Junior Medical Officers].
Improved and better
documentation
’Increase in documentation of pain scores at rest and movement due to a change in hospital paper work.’
’Audits allow for identification of specific weaknesses in a process e.g. the lack of a pain score in the patient observation
chart. It is these system changes that have the most lasting effects’
Improvement at discharge for
patients
’Improved patient information process to understand analgesics prescribed at discharge’
Use of benchmarking for
improvement
’It was great to have local data for feedback’
Patient education/counselling ’Improved provision of information to patients.’
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in some hospitals being unable to complete the project as
they were not able to retain project staff.
Other challenges for collaborative work include the
coordination of activities across all sites within defined
timeframes e.g. hospital recruitment, obtaining ethics
approval and data entry/submission to enable timely
reporting of state and national results. Delays in obtaining
ethics approval, variation in rate of presentation of eligible
patients across participating sites, management of project
workload and staff leave may influence the ability of the
project teams in meeting key milestones/deadlines.
A challenge for most quality improvement activities at a
hospital level is the rotation of junior hospital staff to
other clinical areas. Repeated education is therefore
required as new staff are rotated through the targeted clin-
ical area. This was highlighted by comments from the eva-
luation survey. Conversely rotating staff take the learnings
with them to other clinical areas which may facilitate the
spread of the educational messages to a wider audience.
To promote sustainability and spread of improvements
achieved, the NPS provides the electronic DUE tool as a
stand-alone version freely available online after the com-
pletion of the project [28]. Hospitals are encouraged to
undertake further audits of their practice and continue
quality improvement.
Conclusion
This national program has facilitated the participation of
a substantial number of hospitals to undertake DUE,
and deliver standardized and consistent key educational
messages across Australia. The model has been per-
ceived by hospitals to be effective in helping hospitals
achieve improvements in patient care.
Additional material
Additional file 1: Multicentre Drug Use Evaluation survey.
Multicentre DUE survey questions.doc.
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